Literature DB >> 1346282

Anti-GOR and hepatitis C virus in autoimmune liver diseases.

G Michel1, A Ritter, G Gerken, K H Meyer zum Büschenfelde, R Decker, M P Manns.   

Abstract

Anti-GOR is an autoantibody found in hepatitis C virus (HCV) infection. We have studied the specificity of this antibody for HCV infection in various groups of autoimmune liver diseases. Anti-HCV was detected by a second generation HCV enzyme-linked immunosorbent assay in 14 of 29 patients with liver-kidney-microsomal (LKM-1) -antibody-positive autoimmune hepatitis type 2 and in all 6 control patients with HCV-RNA-positive chronic hepatitis C. Anti-HCV was not found in those with antinuclear-antibody-positive autoimmune hepatitis type 1 (10 patients), with soluble-liver-protein-antibody-positive autoimmune hepatitis type 3 (8), with primary biliary cirrhosis (9), with systemic lupus erythematosus (SLE) (10), or in healthy controls (13). Anti-GOR was detected in 11 of 14 patients with autoimmune hepatitis type 2 who were all positive for anti-HCV but only in 1 of 15 LKM-1 patients who were negative for anti-HCV. We did not find anti-GOR in any other group of autoimmune liver disease, SLE, or control sera, but this antibody was detected in 3 of 6 patients with chronic hepatitis C. Autoimmune hepatitis type 2 patients who were anti-GOR positive and anti-HCV positive were less likely to be female, were older (p less than 0.001), and had lower LKM-1 antibody titres (p less than 0.001), lower disease activity, and responded less effectively to immuno- suppression than did those who were anti-HCV negative/anti-GOR negative. The findings show that anti-GOR reflects HCV-specific autoimmunity. HCV seems to induce autoimmunity to both GOR (an HCV-specific autoepitope) and LKM-1 (an epitope that is also recognised by autoimmune hepatitis sera of a different cause). Anti-GOR and LKM-1 antibodies contribute to a better differentiation of chronic hepatitis, a finding that has therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346282     DOI: 10.1016/0140-6736(92)91332-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Autoimmune hepatitis.

Authors:  E A Roberts
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

Review 2.  Autoimmunity in liver diseases.

Authors:  C P Strassburg; P Obermayer-Straub; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Assessment of histological features and outcome of interferon therapy in chronic hepatitis C.

Authors:  N Kumagai; S Kuramochi; K Toda; N Iwabuchi; K Tsuchimoto; S Tsunematsu; H Saito; T Morizane; M Tsuchiya; H Ishii
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

4.  'Relapse' of chronic active hepatitis--not always what it seems.

Authors:  A F Muller; P J Toghill; P Smith
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

5.  Chronic hepatitis C and autoimmunity: good response to immunosuppressive treatment.

Authors:  A Tran; S Benzaken; G Yang; S Schneider; A Doglio; A Rampal; P Rampal
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

6.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

7.  Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.

Authors:  J M Pawlotsky; L Deforges; S Bretagne; C André; J M Métreau; V Thiers; E S Zafrani; M Goossens; J Duval; J P Mavier
Journal:  Gut       Date:  1993       Impact factor: 23.059

8.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia.

Authors:  A Gabrielli; A Manzin; M Candela; M L Caniglia; S Paolucci; M G Danieli; M Clementi
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.